Fig. 4: Cumulative relapse-free survival (RFS) of patients of different ages. | Blood Cancer Journal

Fig. 4: Cumulative relapse-free survival (RFS) of patients of different ages.

From: Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial

Fig. 4

A Cumulative RFS curves of patients <60 years old illustrated a significant benefit in the EPAG+tacrolimus group (P = 0.048). B Cumulative RFS curves of patients ≥60 years old illustrated no significant difference between the treatment groups. EPAG eltrombopag.

Back to article page